陇神戎发(300534) - 2017 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2017 was CNY 57,847,180.08, representing a 25.30% increase compared to CNY 46,165,129.02 in the same period last year[7] - Net profit attributable to shareholders decreased by 25.85% to CNY 7,651,783.13 from CNY 10,319,845.90 year-on-year[7] - The net profit after deducting non-recurring gains and losses fell by 44.06% to CNY 5,631,439.38 compared to CNY 10,066,545.90 in the previous year[7] - The basic earnings per share decreased by 44.40% to CNY 0.0883 from CNY 0.1588 year-on-year[7] - The company achieved operating revenue of 57.84 million RMB in Q1 2017, representing a 25.30% increase year-on-year[24] - The net profit attributable to shareholders decreased by 25.38% to 7.65 million RMB compared to the same period last year[24] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 44.06% to 5.63 million RMB year-on-year[24] - The gross profit margin for the quarter was approximately 13.5%, down from the previous year's margin[44] - The company reported an operating profit of CNY 6,648,171.75, a decrease from CNY 11,862,170.11 in the prior period[44] - The total comprehensive income for the first quarter was CNY 7,781,827.17, compared to CNY 10,428,503.87 in the previous period, reflecting a decrease of approximately 25.8%[49] Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of CNY 8,593,346.93, worsening from a net outflow of CNY 7,559,348.07 in the same period last year[7] - Cash and cash equivalents decreased by 36.42% compared to the beginning of the period, primarily due to payments for project costs[21] - The company's cash and cash equivalents decreased to 79,032,429.33 RMB from 124,302,626.49 RMB, reflecting a decline of approximately 36.3%[35] - Cash inflow from operating activities was CNY 48,545,427.42, down from CNY 60,751,220.52, indicating a decline of about 20%[51] - The net cash flow from operating activities was negative at CNY -8,593,346.93, compared to CNY -7,559,348.07 in the previous period, worsening by approximately 13.7%[52] - The cash and cash equivalents at the end of the period stood at CNY 79,032,429.33, down from CNY 109,100,839.14, a decline of approximately 27.5%[53] - The company’s cash and cash equivalents decreased by CNY 45,270,197.16 during the period, compared to a decrease of CNY 32,941,548.19 in the previous period, indicating a worsening cash position[53] Assets and Liabilities - The total assets at the end of the reporting period were CNY 773,259,673.30, a 1.28% increase from CNY 763,476,182.16 at the end of the previous year[7] - As of March 31, 2017, the total assets amounted to 773,259,673.30 RMB, an increase from 763,476,182.16 RMB at the beginning of the period[38] - The company's total assets increased to CNY 785,252,165.22 from CNY 762,337,308.36, showing a growth of about 3.9%[41] - The total liabilities rose to CNY 74,035,757.18, compared to 58,914,048.24 in the previous period, indicating an increase of approximately 25.7%[41] - Total current liabilities increased to 44,873,995.10 RMB from 40,080,607.84 RMB, marking an increase of about 12.0%[37] - The company's total equity reached 711,399,511.53 RMB, up from 703,736,407.65 RMB, reflecting a growth of approximately 1.9%[38] - The owner's equity totaled CNY 711,216,408.04, up from CNY 703,423,260.12, reflecting a slight increase of about 1.1%[41] Accounts Receivable and Inventory - Accounts receivable increased significantly, reaching CNY 15,461.56 million by the end of March 2017, accounting for 59.66% of current assets[14] - Accounts receivable increased to 154,615,602.02 RMB from 135,893,531.38 RMB, representing a growth of about 13.4%[35] - Inventory rose to 19,470,646.11 RMB from 16,400,159.07 RMB, indicating an increase of approximately 19.1%[35] Operational Risks and Market Strategy - The company relies heavily on its main product, Yuanhu Zhitong Pill, which accounted for 98.13% of total drug sales in Q1 2017[10] - The company is expanding its market for Yuanhu Zhitong Pill while promoting other unique products to build a product lineup[10] - The company faces risks related to the expiration of the protection period for its main product, Yuanhu Zhitong Pill, which is set to expire on June 17, 2017[11] Investment and Procurement - The company's investment activities generated a net cash flow decrease of 77.54% year-on-year, mainly due to increased project payments[23] - The production base for 10 billion granule pills has commenced operations, with full production capacity expected to be released over five years[24] - The top five suppliers accounted for 90.37% of total procurement, with a 7.35 percentage point decrease year-on-year, indicating normal procurement fluctuations[25] Shareholder Returns - The company reported a cash dividend of 1.00 RMB per 10 shares and a bonus issue of 3 shares for every 10 shares held, along with a capital reserve conversion of 22 shares for every 10 shares held[29]